Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 4 1Phase 3 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Hyperuricemia 3Lymphoma 2Leukemia 2Burkitt Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Nutritional and Metabolic Diseases 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myeloid, Acute 1Dendritic Cell Sarcoma, Interdigitating 1Congenital Abnormalities 1Blast Crisis 1

Interventions

rasburicase 4Urate Oxidase 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Hyperuricemia × Urate Oxidase × Clear all
NCT00664144 2012-03-07

GRAAL2

Sanofi

Phase 2 Terminated
33 enrolled

Hyperuricemia

NCT00631579 2009-10-02

Rasburicase as a Uricolytic Therapy for Hyperuricemia in Patients With Leukemia or Lymphoma

Sanofi

Phase 2 Completed
50 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Hyperuricemia

NCT00290992 2009-03-30

Rasburicase for Hyperuricemia

Sanofi

Phase 2 Completed
30 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Nutritional and Metabolic Diseases, Hyperuricemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡